Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
EphA2 Chimeric Antigen Receptor (CAR) T cell Therapy for Children with Bone Tumours: A Phase I Clinical Trial
2026
Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension
2026
Development of Novel Small Molecules for Therapeutic Intervention in Pulmonary Arterial Hypertension (PAH)
2026
Defining the role of host microRNAs in COVID-19”
2026
Transforming corneal stem cell-based therapies with innovative bioengineered technologies
2026
Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges
2026
Systemically delivered small molecule STING agonists as next generation cancer immunotherapies
2026
High-Throughput Drug Sensitivity Screening in Multiple Myeloma
2026
Aseptic process simulation runs enabling clinical manufacture of Primaverah for Phase 1/2A clinical use
2026
Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness
2026
Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies
2026
Pre-clinical optimisation studies on a new antimalarial drug lead
2026
Hit to lead optimisation of novel drug candidates targeting mental health and neurodegenerative diseases.
2026
Using zebrafish to assess the potential of mitochondrial-associated genes as therapeutic targets for metastatic cancer
2026
High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma
2026
Advancing a novel therapy for the prevention of haemolytic disease of the foetus and newborn
2026
Targeting sterol metabolism as a way to kill parasitic worms
2026
Discovery of MyD88 inhibitors for novel anti-inflammatory and anti-cancer therapy
2026
Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer
2026
Developing anti-capsid therapeutics for HTLV-1
2026
Development of cryopreserved wound patches with stem cells ready for thawing at point of care
2026
Development of new nano-platforms for the treatment of triple negative breast cancer (TNBC).
2026
Epigenetic-directed drug development for type I interferonopathies
2026
Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers
2026
ADME and PK evaluation of VAST preclinical candidates for postsurgical pain
2026
Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells
2026
Restoring the efficacy of chemotherapy in drug resistant cancers
2026
Development of targeted mRNA vaccines for liver cancer
2026
LRP1 Antagonist to Block Interneuronal Spread of Tau in Alzheimer's Disease
2026
Development of CaMKK2 inhibitors as new cancer therapies
2026
Optimisation of a new class of inflammation-resolving GPCR agonists for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF)
2026
Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum
2026
Discovery of new treatments for brain development disorders linked to epigenetic regulatory genes
2026
GP130 Agonists for the treatment of brain and spinal cord injury
2026
A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases
2026
Blitz-OM- development of a slow-release anti-biofilm treatment to prevent the need for recurrent grommet surgery
2026
Development of an Oral Solid Dosage Formulation of Novel Prostate Cancer TRPV6 Inhibitor QED-203
2026
Discovery of Prophage-Inducing Compounds as a Novel Strategy for Targeted Antibacterial Therapy
2026
Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance
2026